Selective Cbl-b Inhibitor Compounds for Immune Response Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors targeting Casitas B-lineage lymphoma (Cbl) proteins, specifically Cbl-b, to modulate immune responses and treat conditions mediated by Cbl-b, such as cancer.
Innovation Solution
Development of compounds represented by Formula I and Formula II, which inhibit Cbl-b activity, enhance immune cell activity, and treat diseases mediated by Cbl-b, including cancer, through administration to a subject.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule inhibitors are developed against Cbl-b to modulate immune responses, then therapeutic efficacy for cancer and immune-mediated conditions is improved, but development complexity and validation requirements increase
Solution Approach 1:
The patent segments the validation process into distinct phases: in vitro validation using defined cell lines and assays, in vivo validation using controlled animal models, and clinical translation protocols. This segmentation allows systematic evaluation of Cbl-b inhibitors while managing development complexity through structured milestones and criteria for progression to next stages.
Solution Approach 2:
The patent employs intermediary validation models including defined cell lines (e.g., Cbl-b dependent cancer cell lines), animal models with controlled Cbl-b expression, and preclinical assay systems. These intermediaries bridge the gap between basic Cbl-b biology and clinical application, enabling rigorous efficacy assessment before human trials.
2Adaptability or versatility
If selective Cbl-b inhibitors are developed to enhance immune cell activity, then immune response modulation is improved, but off-target effects and safety issues may arise
Solution Approach 1:
The patent emphasizes developing inhibitors with selective activity specifically against Cbl-b rather than pan-E3 ligases or other targets. This local quality approach ensures that immune modulation is achieved through Cbl-b-specific mechanisms while minimizing off-target effects on other ubiquitin ligases, immune cells, or non-immune tissues.
Solution Approach 2:
The patent replaces broad-spectrum immunomodulatory approaches with a more precise molecular mechanism targeting Cbl-b's specific role in immune regulation. By substituting non-specific immune stimulation with targeted Cbl-b inhibition, the therapy achieves adaptability in immune response modulation while eliminating harmful off-target effects associated with non-specific approaches.
3Measurement precision
If preclinical validation models are established for Cbl-b inhibitors, then efficacy assessment is improved, but time and resource requirements increase
Solution Approach 1:
The patent establishes defined cell lines and preclinical models before inhibitor development begins. These preliminary action models include Cbl-b dependent cancer cell lines with characterized phenotypes and animal models with controlled Cbl-b expression, enabling immediate and precise efficacy assessment once inhibitors are synthesized, thereby reducing overall validation time.
Solution Approach 2:
The patent develops multi-functional validation models that can assess multiple aspects of inhibitor efficacy simultaneously. For example, defined cell lines can evaluate both proliferation inhibition and immune modulation effects, while animal models can assess tumor efficacy and safety in a single study design, reducing the number of separate validation experiments required.
Data Source
AI summary
Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.